Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.33 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
| ▸ | KDM1A | O60341 | 4/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937266 | 0.88 | HTR2C (0.36) | HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL25937260 | 0.81 | MCHR1 (0.40) | HTR2AHTR2CHTR2BKDM1ASLC6A2 | |
| SCHEMBL25937272 | 0.81 | MCHR1 (0.40) | HTR2AHTR2CHTR2BKDM1ASLC6A2 | |
| SCHEMBL25937271 | 0.78 | HTR2C (0.32) | HTR2CHTR2BSLC6A4 | |
| SCHEMBL25937264 | 0.74 | S1PR5 (0.31) | — | |
| SCHEMBL25937262 | 0.74 | SCD (0.34) | KDM1A | |
| SCHEMBL17072236 | 0.73 | KDM1A (0.33) | KDM1A | |
| SCHEMBL25937293 | 0.72 | S1PR4 (0.37) | — | |
| SCHEMBL25937261 | 0.70 | MCHR1 (0.39) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL25937273 | 0.70 | MCHR1 (0.39) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | HTR2A 4678/4885HTR2C 4504/4885HTR2B 4686/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | HTR2A 4678/4885HTR2C 4504/4885HTR2B 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.